Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia

In this RCT (n=240), no cognitive or functional benefits were observed with intranasal insulin treatment vs. placebo over a 12-month period in primary intention-to-treat cohort (mean score change on Alzheimer Disease Assessment Scale 0.0258 points; 95% CI, −1.771 -1.822; p=0.98).


JAMA Neurology